Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06473871 · 2 trials · 2 indications
Physician global assessment was performed using the overall opinion question of the POSAS scale. Physicians were asked to rate the severity of the participant's scar compared to normal skin. The overall opinion scale score ranged from 1 (normal skin) to 10 (worst imaginable scar). Within participant treatment difference was assessed between the treatment regimens each participant received.
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects
The number and percentage of subjects that experienced injection site reactions will be analyzed.
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of subjects
| Arm | Type | Description |
|---|---|---|
| Group 1 | ACTIVE_COMPARATOR | - |
| Group 2 | ACTIVE_COMPARATOR | - |
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | - |
| Cohort 4 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-06473871 | DRUG | Single dose administered by injection four different times |
| 80 mg PF-06473871 | DRUG | 80 mg of PF-06473871 or placebo |
| 160 mg PF-06473871 | DRUG | 160 mg of PF-06473871 or placebo |
| 320 mg PF-06473871 | DRUG | 320 mg of PF-06473871 or placebo |
| 480 mg PF-06473871 | DRUG | 480 mg of PF-06473871 or placebo |
Inclusion Criteria: * Subjects must have hypertrophic (raised) breast scars from previous surgery * Subjects must be healthy Exclusion Criteria: * Currently pregnant or pregnant during the 6 months, prior to inclusion in the study or breast-feeding. * Presence of history of breast cancer
PF-06473871 is an investigational small molecule being studied for the reduction of hypertrophic skin scarring and in healthy adults. It is developed by Pfizer, Inc. (PFE). The drug is not approved and remains in clinical development.
PF-06473871 is developed by Pfizer, Inc., which trades under the ticker PFE. The company is conducting clinical trials to evaluate the drug's safety and efficacy for reducing hypertrophic skin scarring.
PF-06473871 is in clinical development. One completed trial was a Phase 2 study for reducing hypertrophic scars, and another was a Phase 1 study in healthy adults. The drug is investigational and not yet approved.
PF-06473871 has two completed trials: NCT01730339, a Phase 2 study in 103 patients for reducing hypertrophic scars from recurring post-revision surgery, and NCT01753791, a Phase 1 study in 32 healthy adults in Belgium.
No alternative names for PF-06473871 have been disclosed. It is identified solely by its compound number in clinical trial records.